NEW DATA SHOW ORAL FERRIC MALTOL (FERACCRU®) MAY BE A COST-EFFECTIVE ALTERNATIVE TO INTRAVENOUS (IV) CARBOXYMALTOSE WITH AT LEAST AS GREAT BENEFITS IN THE QUALITY OF LIFE OF PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INFLAMMATORY BOWEL DISEASE (IBD)
19 February 2020
NORGINE B.V. ENTERS INTO EXCLUSIVE LICENCE AND DISTRIBUTION AGREEMENTS FOR THE COMMERCIALISATION OF PLENVU® IN A NUMBER OF COUNTRIES IN LATIN AMERICA, SOUTHERN AFRICA, CENTRAL AND EASTERN EUROPE
12 February 2020
CORPORATE MEDIA RELEASE
NORGINE IS COMMITTED TO THE PREVENTION OF COLORECTAL CANCER
AMSTERDAM. The Netherlands, Monday 5 March 2018, 08:00 AM CET. Norgine B.V. today announced its continued support to the European Colorectal Cancer awareness campaign throughout the month of March 2018 #Time4Change, #ECCAM18.
Norgine is a market leader in providing bowel cleansing and colonoscopy products which aim to facilitate high quality colonoscopy. Colonoscopy is a vital screening procedure to detect and remove adenomas and polyps that can result in colorectal cancer. Colorectal cancer is the second most common cause of cancer-related mortality in Europe, with over 447,000 new diagnoses every year.[i] Colorectal cancer is largely preventable, with early detection being associated with a 90% cure rate.[ii]
Norgine’s bowel cleansing and colonoscopy portfolio includes KLEAN-PREP®, MOVIPREP®, ENDOCUFF VISION® and PLENVU®. http://www.expertiseincolonoscopy.com/
As a leader in colonoscopy, Norgine has been collaborating with key European patient organisations in order to increase the detection of colorectal cancer and to help improve patients’ quality of life. Click here to view the full list of all organisations to whom Norgine provides support.
Notes to Editors:
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.
Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
Isabelle Jouin, T: +44 (0)1895 826237
Follow us @norgine
[i] Epidemiology of colorectal cancer in Europe. Source: GLOBOCAN 2012
[ii] Bowel Cancer UK. Available at https://www.bowelcanceruk.org.uk/about-bowel-cancer/screening/. Accessed on 2 March 2018